Ponatinib-Induced Pityriasis Rubra Pilaris-Like Adnexal Dysmaturation: A Case Report

This case report describes a rare skin reaction resembling pityriasis rubra pilaris (PRP) in an 18-year-old Taiwanese woman following treatment with ponatinib, a tyrosine kinase inhibitor (TKI) used for certain leukemias. The patient developed erythematous papules and plaques after starting ponatinib, which resolved with topical treatments and temporary discontinuation of the drug. Histological examination revealed adnexal dysmaturation, a novel finding not previously associated with ponatinib. The report highlights the importance of recognizing such cutaneous side effects to manage them effectively without interrupting cancer treatment. The study was ethically approved, and no conflicts of interest were reported.